Michael Choi
University of California, San Diego · UC San Diego Moores Cancer Center · University of Calilfornia Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Choi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04981912 · Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL PatientsUniversity of California, San Diego · completed · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · principal investigator
- Ph1NCT03422393 · Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibMichael Choi · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph1/Ph2NCT03088878 · A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid MalignanciesOncternal Therapeutics, Inc · completed · B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma · principal investigator
- Ph1NCT02784834 · Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLLMichael Choi · terminated · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph1NCT02611908 · Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.Michael Choi · withdrawn · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02371577 · Evaluation of the Immune Restoration Potential Of LenalidomideUniversity of California, San Diego · withdrawn · Chronic Lymphocytic Leukemia (CLL) · principal investigator
- Ph2NCT02371590 · Lenalidomide and Obinutuzumab for Previously Untreated CLLUniversity of California, San Diego · withdrawn · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT02222688 · UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic LeukemiaThomas Kipps · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02046928 · Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)Ångstrom Pharmaceuticals · terminated · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL · principal investigator
- Ph1NCT01955668 · AZD6738 First Time in Patient Multiple Ascending Dose StudyAstraZeneca · completed · 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 292 PubMed records, and a shared surname and initials can bring in a namesake. All 292 on PubMed
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.Nat Med · 20181,396 citationsRCR 45.0
- 627 citationsRCR 18.8
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.J Clin Oncol · 2015472 citationsRCR 13.0
- 344 citationsRCR 11.6
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.Lancet Oncol · 2018324 citationsRCR 10.2
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.J Clin Oncol · 2017248 citationsRCR 7.3
- 235 citationsRCR 15.5
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.Cell Stem Cell · 2018177 citationsRCR 5.7
- Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects.Clin Nutr · 2003169 citationsRCR 4.6
- Mycophenolate mofetil treatment for primary glomerular diseases.Kidney Int · 2002163 citationsRCR 5.2